Voyageur Pharmaceuticals CEO recaps milestone achievements in 2024 and outlines goals for 2025

Proactive - Interviews for investors

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to share details from a recently released Letter from the CEO, highlighting the company’s significant achievements in 2024 and its ambitious plans for 2025. Willis reflected on 2024 as a transformative year for Voyageur, with the company entering into a Letter of Intent with a large multinational pharmaceutical company. This collaboration aims to improve production efficiencies and expand Voyageur’s presence in the contrast media market. Both parties are actively working toward a definitive agreement, expected in early 2025. Voyageur introduced five new Health Canada-licensed barium contrast products aimed at raising the bar for medical imaging standards and enhancing diagnostic precision for healthcare professionals. This accomplishment followed 18 months of dedicated research and development. The company secured a $2.7 million sales distribution contract for its SmoothX 2% Barium Contrast product, solidifying its market presence in Latin America. Regulatory approvals are in progress, with sales slated to commence in the second half of 2025. Additionally, Voyageur is engaging with global distributors to broaden its reach. Voyageur is entering 2025 with a clear roadmap for advancing its product pipeline and market position, which includes extensive testing of its barium contrast formulations in human subjects is set to begin, with a focus on ensuring safety and efficacy in clinical settings. Voyageur aims to secure FDA approvals for its barium contrast products, demonstrating compliance with rigorous U.S. regulatory standards. A major initiative for 2025 involves advancing its iodine contrast drug development in the U.S. The goal is to produce the lowest-cost iodine contrast drugs in the market. Preliminary bench-scale testing has already commenced, and the company is laying the groundwork for full-scale production. With North America currently relying 100% on imported radiology drugs, Voyageur is focused on addressing critical mineral supply constraints. The company is working to establish the first secure, vertically integrated supply chain for radiology drugs in North America, aiming to fill critical gaps in the industry. As Willis explained, these efforts underscore Voyageur’s commitment to innovation and its vision to redefine the radiology drug industry by providing secure, cost-effective, and high-quality solutions for healthcare professionals. With its robust pipeline and strategic partnerships, Voyageur is well-positioned for sustained growth and success in 2025 and beyond. #proactiveinvestors #voyageurpharmaceuticalsltd #tsxv #vm #vyyrf #ctscan #xray #BrentWillis, #RainCage, #Nanoscience, #MRI, #CTScan, #MedicalBreakthrough, #Fullerenes, #Vanadium, #Gadolinium, #Bismuth, #Iodine, #Radiology, #MedicalInnovation, #DrugDevelopment, #Healthcare, #ScientificBreakthrough,